FDA fast-tracks experimental daily pill for lupus brain fog issues
Oral therapy EG-501 aims to shield neurons from immune-driven damage
Written by |
The U.S. Food and Drug Administration (FDA) has granted fast track designation to EG-501, an experimental oral therapy being developed by Evergreen Therapeutics to treat cognitive impairment associated with neuropsychiatric systemic lupus erythematosus (NPSLE-CI), a form of lupus that’s marked by neurological problems.
The FDA’s fast track status is designed to expedite the development and review of experimental medicines for serious conditions with high unmet medical needs. For Evergreen, the designation provides key regulatory benefits, including more frequent meetings and communication with the FDA throughout the clinical trial process.
“We are very pleased to receive Fast Track designation for our EG-501 program, which underscores the urgent need to advance new treatment options for the NPSLE-CI community,” said Tom Du, MD, PhD, Evergreen’s CEO, said in a company press release. “We look forward to working closely with the FDA as we advance the clinical development of EG-501 and strive to bring this potential therapy to patients as quickly as possible.”
Systemic lupus erythematosus (SLE) is an autoimmune disorder in which the body’s immune system mistakenly attacks healthy tissues and organs. NPSLE-CI is a specific subtype that affects the central nervous system, leading to neurological complications such as memory issues, brain fog, and other cognitive impairments.
Protecting brain cells from immune damage
In people with NPSLE-CI, the disease-driving immune attack can damage the blood-brain barrier, the protective shield of cells that normally stops harmful toxins in the blood from entering the brain.
This damage, combined with the overactivation of specialized brain immune cells called microglia, leads to a process known as glutamate excitotoxicity. In simple terms, this is when nerve cells start firing more than they should, using a messenger called glutamate, which damages the nerves and leads to problems with cognitive processing and attention.
EG-501 is designed to block the activity of the NMDA receptor, a brain protein that may be involved in glutamate excitotoxicity as well as microglial activation. By keeping this receptor in check, the therapy aims to restore function and provide long-lasting protection to nerve cells.
The therapy was evaluated in a Phase 2 clinical trial (NCT07281105) that compared EG-501 to a placebo in 56 adults with NPSLE-CI. The trial met its primary goal, with results showing that the 43 participants who completed the three-month study achieved statistically significant improvements in cognitive performance compared to those on the placebo. Benefits were also seen in multiple areas of cognitive function, according to Evergreen.
Leave a comment
Fill in the required fields to post. Your email address will not be published.